The identity of our clients must remain strictly confidential, but the following examples are representative of the wide range of services we have provided to diverse clients.
Large pharmaceutical corporations
Critical analysis of clinical study protocols and study reports
Problem solving in data analysis and interpretation
Writing of regulatory documents
Consulting for effective communication of brand attributes and benefits
Publication of pivotal clinical trials, phase IV studies and position papers in peer-reviewed journals
Presentation of study results at major international congresses
Competitor analyses
Small and medium-size biotech and pharmaceutical enterprises (China, Europe, Japan and USA)
Management of collaborations with academic research institutions
Problem solving in data analysis and interpretation
Consulting for optimal positioning of new therapeutic candidates
Publication of clinical trials in peer-reviewed journals
Analysis and publication of comparative-effectiveness studies
Presentation of study results at international congresses
Start-ups and small emerging biopharmaceutical companies (Europe, Israel and USA)
Evaluation of the commercial values of lead projects
Addressing the problems of new formulations of existing drugs
Scientific and medical advice in preclinical and early development
Consulting for the design of proof-of-concept studies
Identification of suitable biomarkers for assessing therapeutic responsiveness
Problem solving in the interpretation of study results
Strategic advice on regulatory issues
Identification of alternatives to proof-of-concept indications for therapeutic candidates under development
Creation of communication plans to attract the interest of investors and potential partners
Publication of preclinical and Phase I-IIa studies in peer-reviewed journals
Presentation of study results at international congresses
Public and private investors (Europe and USA)
Analysis of the risks and commercial potentials of new technologies, diagnostics or drug candidates
Evaluation of the exploitability at the clinical levels of projects in the research/discovery or preclinical stage
